Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lyxumia
Drug ID BADD_D01335
Description Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus (T2DM). It is sold under the brand name Adlyxin by Sanofi-Aventis. Adlyxin recieved FDA approval July 28, 2016 [L763].
Indications and Usage For use as an antihyperglycemic agent in the treatment of T2DM [FDA Label].
Marketing Status Prescription
ATC Code A10BJ03
DrugBank ID DB09265
KEGG ID D09729
MeSH ID C479460
PubChem ID Not Available
TTD Drug ID D05MKA
NDC Product Code 0024-5745; 0024-5747
Synonyms lixisenatide | DES-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide | Adlyxin | AQVE-10010 | ZP10A peptide | ZP 10 | ZP-10 | Lyxumia | AVE 010 | AVE-010 | AVE 0010 | AVE0010 | AVE-0010
Chemical Information
Molecular Formula Not Available
CAS Registry Number 320367-13-3
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Arrhythmia02.03.02.001--Not Available
Back pain15.03.04.005--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspepsia07.01.02.001--
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site pruritus08.02.03.013; 23.03.12.007; 12.07.03.014--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Palpitations02.01.02.003--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tachycardia02.03.02.007--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Connective tissue disorder15.06.01.006--Not Available
Infestation11.09.01.001; 23.09.05.001--Not Available
Malnutrition14.03.02.004--Not Available
Cystitis viral20.03.02.004; 11.05.04.021--Not Available
The 1th Page    1    Total 1 Pages